ESR1 and breast cancer: Since previous studies have also shown that chronic bortezomib exposure causes a reduction of ERα associated with decreased ERα mRNA level in breast cancer cell lines [52], we also examined whether bortezomib could enhance WT161-induced ERα downregulation.